- Home
- BIIB vs ATO Comparison
BIIB vs ATO Comparison
Compare BIIB & ATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ATO
- Stock Information
- Founded
- BIIB 1978
- ATO 1906
- Country
- BIIB United States
- ATO United States
- Employees
- BIIB N/A
- ATO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ATO Oil/Gas Transmission
- Sector
- BIIB Health Care
- ATO Utilities
- Exchange
- BIIB Nasdaq
- ATO Nasdaq
- Market Cap
- BIIB 18.8B
- ATO 24.4B
- IPO Year
- BIIB 1991
- ATO 1987
- Fundamental
- Price
- BIIB $132.82
- ATO $152.28
- Analyst Decision
- BIIB Buy
- ATO Buy
- Analyst Count
- BIIB 27
- ATO 9
- Target Price
- BIIB $188.17
- ATO $156.81
- AVG Volume (30 Days)
- BIIB 1.3M
- ATO 809.5K
- Earning Date
- BIIB 07-31-2025
- ATO 08-06-2025
- Dividend Yield
- BIIB N/A
- ATO 2.29%
- EPS Growth
- BIIB 26.39
- ATO 8.10
- EPS
- BIIB 10.12
- ATO 7.25
- Revenue
- BIIB $9,816,400,000.00
- ATO $4,485,994,000.00
- Revenue This Year
- BIIB N/A
- ATO $13.27
- Revenue Next Year
- BIIB N/A
- ATO $12.93
- P/E Ratio
- BIIB $13.13
- ATO $21.01
- Revenue Growth
- BIIB 1.59
- ATO 10.60
- 52 Week Low
- BIIB $110.04
- ATO $113.46
- 52 Week High
- BIIB $238.00
- ATO $167.45
- Technical
- Relative Strength Index (RSI)
- BIIB 59.57
- ATO 45.10
- Support Level
- BIIB $123.90
- ATO $149.98
- Resistance Level
- BIIB $134.75
- ATO $155.78
- Average True Range (ATR)
- BIIB 3.50
- ATO 2.19
- MACD
- BIIB 0.28
- ATO -0.03
- Stochastic Oscillator
- BIIB 83.71
- ATO 32.30
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ATO Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.